Only a handful of places left for our September 2026 cohort. Applications close soonApply now →

MSTA
Your future
starts here.

Morpheus8

Also known as: morpheus 8, morpheus8, morpheus

A branded bipolar fractional radiofrequency microneedling platform made by InMode Ltd, delivering 1 MHz RF through detachable single-use tip heads of 12, 24 or 40 pins at selectable depths. Its FDA clearance is for coagulation/contraction of soft tissue and haemostasis, not for any cosmetic outcome.

Evidence status

Manufacturer-supported

Uncontrolled series report improvements in laxity, acne or hidradenitis, but no randomised controlled trial of Morpheus8 has been published and the largest 247-patient cohort was published twice. The FDA 510(k) record contains no clinical performance data, while most device-specific studies involve InMode consultants, sponsorship or concurrent treatments that prevent attribution. Serious RF-microneedling complications reported to FDA include burns, scarring, fat loss, disfigurement and nerve damage; the communication concerns the device class, not Morpheus8 alone.

What Morpheus8 is, and the types available#

Morpheus8 is a branded radiofrequency microneedling platform made by InMode. The listed parent, InMode Ltd, is an Israeli medical-device company traded on Nasdaq as INMD; US 510(k) applications name its affiliate InMode MD Ltd at the same Yokneam address.[6, 2]

The system delivers bipolar radiofrequency at 1 MHz with maximum output of 65 W through detachable, sterile, single-use tip heads containing 12, 24 or 40 pins, plus a shallow “T” tip. FDA documentation lists maximum depths of 0.5 mm for the T tip, 4.0 mm for the 12-pin tip and 7.0 mm for the 24- and 40-pin tips. Current manufacturer material instead describes the 24-pin facial tip as reaching 4–5 mm and the 40-pin body tip as 7 mm with a further 1 mm thermal effect. The marketed “8 mm” is therefore a thermal profile, not 8 mm needle penetration.[1, 8, 7]

“Burst” is InMode's name for sequential delivery at three depths within one cycle. It changes the sequencing of the same bipolar RF energy rather than creating a new energy type. No published clinical comparison of Burst with conventional single-depth delivery is available, so its outcome or risk advantage is unknown.[7, 8][no source found]

Morpheus8 belongs to the RF-microneedling modality. General physics, insulated versus non-insulated electrodes and cross-platform parameter comparison belong to the RF-microneedling topic; the scope here is InMode's specific platform, claims, evidence and safety record.

Use of Morpheus8 in aesthetic practice#

Morpheus8 is a medical device in Great Britain under the UK Medical Devices Regulations 2002. UKCA marking applies, with CE recognition continuing under transitional arrangements. Device regulation governs manufacture, labelling, intended purpose and vigilance; it does not by itself credential an operator.

The device's US FDA route has no UK legal effect. Its current FDA-cleared indication is “use in dermatologic procedures where coagulation/contraction of soft tissue or hemostasis is needed”. Wrinkles, acne scars, cellulite, stretch marks and fat remodelling do not appear as cleared indications. Calling it “FDA cleared” in UK marketing describes a US substantial-equivalence decision, not British authorisation or proof of a cosmetic outcome.[2, 1][2, 1]

England's 2023 consultation proposed RF-plus-microneedling hybrids for the amber tier, above plain microneedling in green. Under that proposal, a non-healthcare professional would need a licence and oversight by a named regulated healthcare professional. It remains a proposal. The August 2025 response said further work was needed before procedures could be placed and recorded calls for more scoping of RF and combination technologies; no licensing scheme is in force.[4][5]

Contraindications and cautions#

The current instructions supplied for the exact console, handpiece, tip and market are the governing contraindication document. Treatment is not appropriate where that document, the device's intended purpose, consumable integrity, practitioner training or named insurance cover cannot be confirmed.

Energy and phototype labelling require particular attention. Above 62 mJ per pin, the FDA-cleared use of the Morpheus8 applicator is limited to Fitzpatrick skin types I–IV. This directly qualifies broad “safe for all skin types” claims and makes energy-specific consent and device labelling more informative than the brand name alone.[2, 1]

Active infection, an undiagnosed lesion, impaired healing and any condition or implant listed by the current manufacturer as incompatible require deferral or clinical clearance. Pregnancy appears as a contraindication in manufacturer investigation narratives within the FDA adverse-event record.[3] Skinipedia does not reproduce a generic device protocol or substitute for the current IFU.

Prior procedures and altered tissue planes matter. A 2026 single-surgeon neck-lift series described fibrosis, loss of normal planes, fascial rigidity and unpredictable fat distribution after earlier energy procedures; Morpheus8 was pooled with eight other modalities and prior surgery, so causation cannot be assigned to this device.[14]

Clinical uses and the evidence behind them#

Soft-tissue coagulation and contraction

This is the narrow FDA-cleared use. The 2020 submission relied on bench and ex-vivo testing of harvested porcine muscle and fat, while every archived Morpheus8 510(k) summary states “Clinical Performance Data: Not Applicable”. The 2023 expansion to “contraction of soft tissue” used the same earlier ex-vivo work and no new bench, animal or clinical data.[2, 1]

Lower-face and neck laxity

The largest series combined Morpheus8 with bipolar RF rather than testing it alone. In 247 patients, the Baker Face/Neck score improved by a mean 1.4 points (SD 1.1); swelling beyond six weeks occurred in 4.8%, hardened areas beyond 12 weeks in 3.2% and marginal mandibular neuropraxia in 1.2% (3/247), all reported as resolving. The cohort was uncontrolled, all six authors declared an InMode relationship, and the same 247 patients were published twice with identical headline outcomes, so they count as one series.[9][10]

Acne and acne scarring

The best-known Morpheus8-specific figure is a three-year acne relapse rate of 24%, compared with 67% after isotretinoin and 75% after ablative laser. It came from a non-randomised single-practice review: only 29 of 139 RF-treated patients reached three years and seven relapsed. The groups were selected clinically rather than randomly, follow-up completeness differed, both authors were InMode consultants and the supplement was sponsored by InMode.[11]

Hidradenitis suppurativa

A 2026 retrospective medical series included 25 patients and analysed efficacy in the 17 who completed at least two sessions. Sixteen of 17 improved, nine (52.9%) reached IHS4-55 and mean IHS4 fell by 4.6±2.5. Pain led 3 of 25 to stop and one patient developed a chest abscess requiring admission and intravenous antibiotics. Hidradenitis is a medical disease; this evidence does not create a cosmetic-practice indication.[12]

Combined surgical rejuvenation

The clearest paper without a declared InMode relationship involved 20 patients given low-energy Morpheus8 and nanofat during facial plastic surgery. Surgery, RF and grafting were confounded, so the device's contribution could not be isolated.[13]

No randomised controlled Morpheus8 trial has been published. The core literature is substantially manufacturer-linked: InMode co-funded or sponsored the relevant supplements, and many authors declared consultancy relationships.[9, 10, 11]

Selecting Morpheus8 treatment#

Selection is tip-, site-, depth-, energy- and indication-specific. The 0.5 mm T tip, 4.0 mm 12-pin tip and 7.0 mm 24- and 40-pin clearances are not interchangeable descriptions of one standard treatment.[1] Manufacturer marketing dimensions also differ from the FDA comparison table, making the current UK-labelled IFU for the installed system the controlling document.[1, 7, 8]

No evidence establishes that Burst delivery improves a clinical outcome or reduces harm relative to single-depth treatment. No head-to-head study shows that Morpheus8 produces an outcome unavailable from another RF-microneedling platform at matched energy and depth.

The published evidence cannot supply a generic setting, pass count, anaesthesia plan, interval or course. Those belong to device-specific training, the current IFU and the responsible clinician's governance. The absence of a randomised protocol comparison makes copying settings from an uncontrolled series particularly unsafe.

Adverse effects and their management#

FDA safety communication

On 15 October 2025, the FDA issued a safety communication about RF microneedling used for dermatologic and aesthetic skin procedures. It stated that serious reported complications include burns, scarring, fat loss, disfigurement and nerve damage, sometimes requiring surgical repair or medical intervention. Its evaluation is ongoing. The communication applies to the device class rather than naming Morpheus8 alone, and it has no direct UK legal force; its safety signal remains clinically relevant.[15]

Morpheus8 adverse-event reports

FDA's MAUDE database held 62 reports naming Morpheus8 as of August 2026: 61 injury reports and one death report. Recurrent narratives included full-thickness burns, grid-shaped scars matching the tip footprint and erythema or hyperpigmentation lasting eight months to 18 months. The death filing was a family member's voluntary report of microneedling in Mexico that did not name a device in the narrative or establish causality.[3]

The 62 reports are not a complication rate. MAUDE is passive, mainly US reporting with no treatment denominator, verification or causality adjudication, and duplicate patient/manufacturer filings occur. It shows the kinds of serious harms reported, not their probability.[3]

Fat loss and altered tissue

Four separate MAUDE filings described unwanted facial fat loss or indentation, some followed by corrective fat transfer. A neck-lift series also found fibrosis and unpredictable fat distribution after prior energy procedures, but pooled Morpheus8 with multiple other modalities.[3, 14]

Infection, pain and neurological injury

The hidradenitis series recorded discontinuation because of pain in 12% and one abscess requiring hospital treatment.[12] The combined 247-patient series recorded three transient marginal-mandibular neuropraxias.[10] Burns, persistent tip-pattern change, new weakness, sensory change, severe pain, blistering, infection or unexpected contour loss require treatment to stop and prompt medical assessment.

Referral and scope boundaries#

Suspected full-thickness burn, infection, ulceration, progressive pigment change, new facial weakness or sensory loss, visual symptoms, tissue indentation or contour collapse requires prompt medical review. Injuries that may involve a medical device also enter the manufacturer's vigilance pathway and the MHRA Yellow Card scheme where applicable.

A client seeking treatment for active acne, hidradenitis or another medical disease requires diagnosis and medical management. Evidence from a retrospective hidradenitis series does not transfer the condition into aesthetic-practice scope.[12]

Where an outcome claim exceeds the UK device's labelled intended purpose, or the practitioner cannot demonstrate device-specific training, insurance and governance, treatment should not proceed. Questions about previous deep energy treatments and surgical tissue planes belong with the operating surgeon before later facial or neck surgery.[14]

Mechanism of action#

Microneedle electrodes place bipolar RF energy at selected depths, generating local resistive heating and zones of coagulation. The pins provide a depth-controlled route that differs from mechanical microneedling. The “Burst” mode sequences energy at three levels within milliseconds.[7, 8]

InMode introduced the phrase “Subdermal Adipose Remodeling Device” in its own product material, and it entered peer-reviewed literature through an InMode-funded Level-4-evidence supplement paper. No human before-and-after imaging, calliper or histology study has measured subcutaneous fat volume or thickness. The claim rests on ex-vivo porcine coagulation and clinical impression rather than measured human fat remodelling.[7, 9][no source found]

Commonly misstated claims#

“Morpheus8 is FDA approved for wrinkles and skin tightening.”

It is FDA cleared through 510(k), not approved through a premarket-approval route. Its indication is coagulation/contraction of soft tissue or haemostasis, and the submissions list no clinical performance data.[1, 2]

Supported statement: Morpheus8 is FDA cleared for a narrow tissue-coagulation/contraction indication; cosmetic outcome claims require separate substantiation.

“The needles penetrate 8 mm.”

The manufacturer's 8 mm figure combines a 7 mm pin depth with a claimed additional 1 mm thermal effect for the body tip. Other tips reach different depths.[1, 7, 8]

Supported statement: maximum mechanical and thermal depth depends on the specific tip; “8 mm” is a marketed thermal profile, not universal needle penetration.

“It is safe for all skin types.”

Above 62 mJ per pin, US cleared labelling restricts use to Fitzpatrick I–IV, and persistent tip-pattern hyperpigmentation appears in adverse-event reports.[1, 2, 3]

Supported statement: suitability depends on phototype, energy, tip, site and current device labelling; a universal all-skin-types claim is unsupported.

“Morpheus8 clinically proves subdermal fat remodelling.”

The phrase originated in manufacturer naming and a manufacturer-funded Level-4 paper. No human study has measured fat volume, thickness or histology before and after treatment.

Supported statement: Morpheus8 can coagulate tissue; beneficial human subcutaneous-fat remodelling has not been measured, while unwanted fat loss has been reported.[3, 7, 9]

Areas of remaining uncertainty#

  • Whether Morpheus8 outperforms another RF-microneedling platform at matched depth and energy; without head-to-head trials, a brand-specific efficacy advantage cannot be claimed.
  • Whether deep treatment causes durable human fat loss and at what threshold; without prospective imaging or histology, neither benefit nor incidence can be quantified.
  • Whether Burst changes outcomes or risk; without comparison, it remains a delivery feature rather than an evidenced clinical advantage.
  • The true rate of serious complications; passive surveillance and conflicted uncontrolled series cannot supply a denominator for consent.
  • The eventual English licensing placement; until legislation is made, the 2023 amber proposal must not be described as law.[4, 5]

Frequently asked questions#

Is Morpheus8 FDA approved for skin tightening?

No. It is 510(k)-cleared for coagulation/contraction of soft tissue or haemostasis, and the clearance did not rely on human clinical performance data.[1, 2]

Does FDA clearance apply in the UK?

No. UK device status follows the UK Medical Devices Regulations, UKCA or accepted CE marking and the manufacturer's UK intended purpose.

Is the 8 mm claim a needle depth?

No. Manufacturer material describes 7 mm pin depth plus a further 1 mm thermal effect for the 40-pin body tip.[7, 8]

Does Morpheus8 remove facial fat?

No prospective human measurement establishes beneficial fat remodelling. Unwanted fat loss and indentation have been reported, including cases requiring corrective fat transfer.[3]

What did the FDA warn about in 2025?

The FDA named reported burns, scarring, fat loss, disfigurement and nerve damage from RF microneedling, sometimes requiring medical or surgical intervention; its evaluation remains ongoing.[15]

References#

Each source is graded by evidence tier. Tier 4 material (manufacturer documents, expert consensus, practitioner experience) is useful for protocol and context, and is never presented as equivalent to independent clinical evidence.

  1. US FDA. 510(k) Premarket Notification K200947, 'InMode System with the Morpheus8 Applicators'. Applicant named in the 510(k) Summary as InMode MD Ltd., Tabor Building, Shaar Yokneam, Yokneam 20692, Israel (the clearance letter is addressed to 'InMode Ltd.'). Substantially equivalent decision 2 July 2020. 21 CFR 878.4400, Class II, product code GEI. Predicate K192695.Tier 1Supports: Cleared Indications for Use, verbatim: 'The InMode System with the Morpheus8 Applicators is intended for use in dermatological procedures for electrocoagulation and hemostasis. At higher energy levels greater than 62 mJ/pin, use of the Morpheus8 (Fractora) Applicator is limited to Skin Types I-IV.' Device specifications: RF Max Output Power 65 Watt; RF Output Frequency 1 MHz; console 46 x 46 x 100 cm, 30 kg; maximal pulse duration up to 74 msec. Applicator comprises a handle plus 'detachable, sterilized, disposable, single use 12, 24, 40 pin and T tip head accessory'. Comparison table, maximal treatment depth for the subject device: 0.5 mm (T tip head), 4.0 mm (12-pin tip head), 7.0 mm (24- and 40-pin tip heads) — against 4.0 mm for the 24/40-pin predicate (K192695); the depth increase is the substantive change in this submission. This is the submission that carries the ex-vivo porcine work: 'The performance and safety of the InMode System with the Morpheus8 Applicators treatment in dermatological procedures requiring electrocoagulation and hemostasis in deeper tissues of up to 5, 6 and 7 mm was evaluated in an ex-vivo tissue study. The study was conducted on a porcine animal model and included a single treatment of two different harvested porcine tissues: muscle and fat utilizing the InMode System with the Morpheus8 applicator 40 pin tip head', with TTC staining to visualise coagulation necrosis. The summary then states 'Animal Performance Data / Histology Data: Not Applicable' and 'Clinical Performance Data: Not Applicable'. Internal inconsistency worth noting: the substantial-equivalence table describes the subject device's indication as 'dermatological and general surgical procedures', while the signed Indications for Use form says 'dermatological procedures' only. Scope limit: this document establishes what FDA cleared and on what evidence. It says nothing about wrinkles, laxity, scarring, cellulite or fat, and it is a US marketing authorisation only.
  2. US FDA. 510(k) Premarket Notification K231790, 'The InMode System with the Morpheus8 Applicators' (Special 510(k), expansion of indications). Applicant InMode MD Ltd., Tabor Building, Shaar Yokneam, Yokneam 20692, Israel. Cleared 20 July 2023. Materially the same indication wording was carried into K240017, 'InMode System with the Morpheus8 90 Applicator', cleared 13 June 2024 (that document names the Morpheus8 90 Applicator and reads 'dermatological' rather than 'dermatologic').Tier 1Supports: Current cleared Indications for Use, verbatim: 'The InMode System with the Morpheus8 Applicators is intended for use in dermatologic procedures where coagulation/contraction of soft tissue or hemostasis is needed. At higher energy levels greater than 62 mJ/pin, the use of the Morpheus8 Applicator is limited to Skin Types I-IV.' Prescription use only (21 CFR 801 Subpart D). The submission states its purpose verbatim: 'The InMode System with the Morpheus8 Applicators is a expansion of indications for the cleared InMode System with the Morpheus8 Applicators (K200947).' Decisively, no new testing was done for the wider wording: 'No new bench performance data is submitted to support this submission. However, the following bench testing, submitted in K200947, is leveraged to support the expansion of Indications for Use' — that leveraged testing being the ex-vivo study 'conducted on two different harvested porcine tissues, muscle and fat'. 'Animal Performance Data / Histology Data: No new animal performance data is submitted to support this submission. Clinical Performance Data: Not Applicable.' The summary adds: 'Any change in the wording of the indications does not refer to a different intended use nor a different performance claim, and thus no additional performance testing is required.' Scope limits: porcine tissue outside the body, tested three years earlier for a different indication; the widened wording ('contraction of soft tissue') was granted with no human clinical data and no new bench data of any kind. Note also that the K240017 file posted on FDA's cdrh_docs archive contains only the clearance letter and the Indications for Use form — it carries no 510(k) summary, so its evidence statements cannot be read from that document.
  3. US FDA. MAUDE — Manufacturer and User Facility Device Experience database, adverse event reports with device brand name 'Morpheus8'. Queried via the openFDA device/event API, 2 August 2026.Tier 1Supports: 62 reports on file, received 2022 (2), 2023 (19), 2024 (19), 2025 (18) and 2026 to date (4). 61 are coded Injury and 1 Death (openFDA data last updated 21 July 2026). Counting distinct reports whose narrative text mentions each theme: burns 15, post-inflammatory erythema or hyperpigmentation 19, scarring 18, allergic or hypersensitivity reaction 12, tip-footprint or grid pattern 8, nerve palsy or neuropraxia 4, fat loss 4. Recurring narratives, quoted verbatim from the report text: 'FULL THICKNESS BURNS ON UPPER ARMS'; 'FULL THICKNESS BURNS ON GLUTEAL FOLD AND THIGHS'; 'FULL THICKNESS BURNS ON ANTERIOR NECK AND MANDIBLE'; 'RESIDUAL PIE IN THE SHAPE OF THE TIP FOOTPRINTS LOCATED IN THE LOWER ABDOMEN ONE AND A HALF YEAR AFTER TREATMENT WITH MORPHEUS8'; 'PIE ON ABDOMEN WITH TIP FOOTPRINTS PATTERN 11 MONTHS AFTER MORPHEUS8 TREATMENT'; 'PIE AND PIH ON HER ABDOMEN ALMOST 8 MONTHS POST MORPHEUS8 TREATMENT'; 'PIH/PIE OVER HER FACE THAT REPLICATE MORPHEUS8 TIP FOOTPRINTS, 8 MONTHS POST TREATMENT'; 'GRID LIKE SCARRING AND HYPERPIGMENTATION'; 'MANDIBULAR NERVE PALSY ON RIGHT SIDE POST MORPHEUS8 TREATMENT MOST PROBABLY DUE TO THE ADMINISTRATION OF NERVE BLOCK'; 'MULTIPLE HYPOPIGMENTED LESIONS OF VARIABLE SHAPE (ROUNDED AND LINEAR) LOCATED IN THE SUBMENTAL AND NECK AREA'; '3 ULCERATIVE LESIONS 3 WEEKS FOLLOWING M8 BODY TX'; a keloid scar; allergic or hypersensitivity reactions managed with antihistamines and corticosteroids (one narrative records 'TOPICAL STEROID USED AND PREDNISONE FOR INFLAMMATION') — no report found describes emergency-department treatment; a single-use sterile tip re-used on a different patient three days later ('IT WAS REPORTED THAT THREE DAYS AFTER THE STERILE TIP WAS USED ON A PATIENT, THE SAME STERILE TIP WAS RE-USED ON A DIFFERENT PATIENT, RESULTING IN A POTENTIAL EXPOSURE TO PATHOGENS'; the follow-up records that both the patient and the tip subsequently tested negative for pathogens); and four independent reports of unwanted facial fat loss, e.g. 'UNWANTED FACIAL FAT LOSS FROM THIS PROCEDURE THAT HAS LEFT ME WITH INDENTATIONS IN MY CHEEK', 'UNWANTED PERMANENT FAT LOSS, CHANGES IN MY FACE STRUCTURE, INDENTATIONS' and treatment that 'RESULTED IN FACIAL FAT LOSS, SCARRING, HYPERPIGMENTATION, AND TISSUE DAMAGE REQUIRING MULTIPLE CORRECTIVE PROCEDURES INCLUDING FACIAL FAT TRANSFERS'. The one Death report (MW5178594, received 7 Nov 2025, voluntary) reads in relevant part: 'MICRONEEDLING WAS PERFORMED ON MY SISTER, [redacted], IN MEXICO, AND SHE DIED DURING THE PROCEDURE ON [redacted] 2025' — a family member's voluntary report that names no device, parameter or causality, and does not name Morpheus8 in the narrative at all. Balance, because it belongs here: InMode's own investigation narratives attribute several of these events to individual hypersensitivity, to high-percentage numbing creams, to aggressive parameters (extra passes, Burst mode with too many passes), and in one case to treatment during pregnancy, which the IFU lists as a contraindication; in several reports InMode states no technical fault was found on inspection. Scope limits, which are severe: MAUDE is spontaneous, voluntary, US-centred passive surveillance with no denominator, no verification and no causality adjudication. The 62 reports carry 159 narrative rows, and the same event is demonstrably filed more than once — manufacturer reports 3010511300-2023-00257, -2025-00982 and -2025-00986 each explicitly cross-reference the patient's own earlier voluntary report (MW5117220, MW5178446, MW5178600). It cannot give an incidence rate. It can only show which harms are being reported and how often they are severe.
  4. Department of Health and Social Care. The licensing of non-surgical cosmetic procedures in England: consultation document. Published 2 September 2023, closed 28 October 2023.Tier 1Supports: Proposes a three-tier green/amber/red model. Green, verbatim: 'procedures with the lowest risk of complications. All practitioners are eligible to perform licensed procedures where they meet agreed standards' — the proposed green list includes 'microneedling', mesotherapy, IPL and LED, superficial peels and micropigmentation. Amber, verbatim: 'procedures with medium risk of complications. Non-healthcare professionals must be licensed and have relevant oversight by a named regulated healthcare professional (who has gained an accredited qualification to prescribe, administer and supervise aesthetic procedures).' The proposed amber list includes 'radiofrequency treatments' and, separately, 'the combination of 2 or more technologies to create a hybrid device. For example, the combination of radiofrequency and microneedling to treat lines, wrinkles, sagging skin, acne scars and stretch marks'. Scope limit: this is a consultation proposal only. It has no legal force and the tier lists were expressly framed as 'includes, but is not limited to'.
  5. Department of Health and Social Care. The licensing of non-surgical cosmetic procedures in England: consultation response. Published 7 August 2025.Tier 1Supports: The government states it will prioritise legislation restricting the highest-risk procedures (naming breast, buttock and genital augmentation with dermal fillers) to CQC-registered providers, and continue developing local authority licensing for lower-risk procedures. Critically for this entry, the response does NOT allocate individual procedures to green, amber or red: it states that 'further work is required to determine where specific procedures will sit in the proposed tiering system and which practitioners should be permitted to carry out certain procedures', and that it is 'not proposing at this stage to remove any of the procedures currently included within the scope of the licensing scheme or associated regulation, nor are we proposing to add any further procedures'. Microneedling and radiofrequency do appear in the substance of the response, not only in the survey tables: the document restates the proposed green list (including 'microneedling') and the proposed amber list (including 'radiofrequency treatments' and 'the combination of 2 or more technologies to create a hybrid device - for example, the combination of radiofrequency and microneedling to treat lines, wrinkles, sagging skin, acne scars and stretch marks'), records that 'several responses also suggested moving radiofrequency into the green category', and records that 'several responses also suggested that further scoping work should be done on the suggested amber procedures of radiofrequency, electrocautery, cryocautery and combination modalities and technologies'. In the survey data, of 7,603 responses coded to at least one procedure, microneedling accounted for 811 (11%). Scope limit: confirms that as of this response no tier placement is settled and no licensing scheme is in force; the amber placement of RF-microneedling hybrids was actively contested in consultation and is expressly reopened.
  6. US Securities and Exchange Commission, EDGAR. InMode Ltd., CIK 0001742692, SIC 3845 (Electromedical & Electrotherapeutic Apparatus), file number 001-39016; registered address Tavor Building, Sha'ar Yokneam, POB 533, Yokneam 2069200, Israel; ticker INMD, exchange Nasdaq. Annual reports filed on Form 20-F as a foreign private issuer (most recent 10 February 2026).Tier 1Supports: Establishes the corporate entity behind Morpheus8: InMode Ltd is an Israeli company, headquartered in Yokneam, listed on Nasdaq under INMD, incorporated in Israel (state code L3) and reporting to the SEC as a foreign private issuer on Form 20-F. FDA correspondence for the Morpheus8 clearances is addressed variously to 'InMode Ltd.' and 'InMode MD Ltd.' at the same Yokneam address. Scope limit: corporate identity and listing status only — this source says nothing about the device's clinical performance.
  7. InMode Ltd. 'InMode Introduces Morpheus8 Body Multi-pulse Burst Technology' (press release, Lake Forest, CA), 20 October 2020, distributed via PR Newswire.Tier 4Supports: Manufacturer's own claims, verbatim: Morpheus8 Body is 'the first and only FDA cleared technology to penetrate tissue with a thermal profile of 8mm'; Burst is described as fractional technology that 'automatically deploys bipolar RF energy to multi-level treatment depths in a single cycle', with 'the ability to target tissue sequentially at three levels, in millisecond intervals'. The product is named in the release as the 'Morpheus8 Body Subdermal Adipose Remodeling Device (SARD)'. Scope limit: marketing copy from the device vendor, not a clinical or regulatory finding. Note the mismatch with source 1: the cleared indication contains no reference to adipose tissue, depth of penetration or body contouring.Funding / interest: Issued by InMode Ltd, the manufacturer and Nasdaq-listed vendor of Morpheus8; every claim in it is a commercial claim by the seller.
  8. InMode Australia (official InMode regional site). 'Morpheus8 | Fractional RF Microneedling Machine' product page. Accessed 2 August 2026.Tier 4Supports: Current manufacturer tip-by-tip depth claims, verbatim: Morpheus8 Prime 'uses 12 microneedles' for peri-orbital and jawline work; Morpheus8 Resurfacing 'delivers fractional radiofrequency energy at shallow depths between 0.5mm and 0.75mm'; Morpheus8 24 Pin 'can penetrate up to 4mm to 5mm'; Morpheus8 Body '(40 microneedles)... can reach up to 7mm with an additional 1mm thermal profile'; Morpheus8 Burst Deep is described as being for deeper tissue treatment of the face and body, without a stated depth figure. The page also asserts 'Clinically proven triple action of ablation, fat coagulation and volumetric heating'. Scope limits: vendor marketing. The 'clinically proven' phrase is unreferenced on the page, and the device's own 510(k) files state that no clinical performance data were submitted. For contrast, InMode's UK site (inmodemd.co.uk) reproduces the company's July 2024 release, which sticks close to the cleared wording: 'Morpheus8 is the first and only fractional radiofrequency (FRF) microneedling technology cleared for contraction of soft tissue. The U.S. Food and Drug Administration (FDA) has cleared the use of the Morpheus8 Applicators for the delivery of fractional radiofrequency use in dermatologic skin procedures where coagulation/contraction of soft tissue or hemostasis is needed.'Funding / interest: InMode's own commercial website; InMode Ltd manufactures and sells the device and its consumable tips.
  9. Dayan E, Chia C, Burns AJ, Theodorou S. Adjustable Depth Fractional Radiofrequency Combined With Bipolar Radiofrequency: A Minimally Invasive Combination Treatment for Skin Laxity. Aesthet Surg J. 2019;39(Suppl_3):S112-S119.Tier 3Supports: This is the article that put 'subdermal adipose remodeling' into the Morpheus8 vocabulary. It states, verbatim: 'The RF microneedling allows for subdermal adipose remodeling and skin tightening. Addition of bipolar RF also tightens the skin by contraction of the underlaying fibroseptal network in addition to induction of neocollagenesis, elastogenesis, and angiogenesis at skin surface temperatures of 40 degrees to 50 degrees C.' It describes the device as 'Fractora modified to Morpheus8 InMode Aesthetic Solutions, Lake Forest, CA', combined with bipolar RF (FaceTite/BodyTite). The authors self-classify it: 'Level of Evidence: 4'. Correcting an earlier reading of this source: the article does report a patient cohort. It states 'We prospectively evaluated 247 patients (224 female, 23 male; mean age, 55 years; range, 26-67 years)', with a pretreatment average Baker Face Neck Classification of 3.1 (SD 1.4), a post-treatment objective improvement of 1.4 points, '93% of patients indicated they were pleased with their results and would undergo the procedure again', and complications of prolonged swelling beyond 6 weeks (4.8%, 12/247), hardened area beyond 12 weeks (3.2%, 8/247) and neuropraxia (1.2%, 3/247), 'which all resolved without further intervention'. Scope limits: this is a manufacturer-co-funded supplement article whose stated purpose is 'to describe the utility' of the combination; there is no control group, no comparator, no blinding, and no histology or imaging of adipose tissue anywhere in it. Most importantly, these are the same 247 patients and the same headline numbers subsequently published as source 10 (Dayan et al, PRS Global Open 2020) — the sex breakdown differs between the two papers (224/23 here, 234/13 there) but n, Baker score, improvement, satisfaction and every complication rate are identical. The two papers are one cohort reported twice, not two independent series.Funding / interest: Declared: 'Dr Dayan is a Consultant to InMode Aesthetic Solutions and Owner of wikiPlasticSurgery.com. Drs Chia and Theodorou are Consultants to InMode Aesthetic Solutions. Dr Burns is a Consultant to Allergan, HINTMD, InMode Aesthetic Solutions, and Sciton.' Funding statement: 'This article was supported by the InMode Corporation (Toronto, Canada), who co-funded the development of this supplement.' All four authors are InMode consultants and the supplement was manufacturer-funded.
  10. Dayan E, Rovatti P, Aston S, Chia CT, Rohrich R, Theodorou S. Multimodal Radiofrequency Application for Lower Face and Neck Laxity. Plast Reconstr Surg Glob Open. 2020;8(8):e2862.Tier 3Supports: Multicentre retrospective review, January 2013 to December 2018, of 247 patients (234 women, 13 men) treated with a combination of bipolar RF (FaceTite) and fractional bipolar RF ('Fractora modified to Morpheus8'). Mean age 55.1 (SD 8), BMI 24.3 (SD 2.4), 9% (23/247) active smokers, mean baseline Baker Face/Neck score 3.1 (SD 1.4); 240/247 (97.2%) done under local anaesthesia. Outcome: Baker score improved by a mean 1.4 points (SD 1.1); 93% said they were pleased and would repeat. Complications: prolonged swelling beyond 6 weeks 4.8% (12/247), hardened area beyond 12 weeks 3.2% (8/247), marginal mandibular neuropraxia 1.2% (3/247), all resolving. Four cadaver dissections were done to correlate neuromuscular anatomy. Scope limits: retrospective, unblinded, no control group, no standardised photography protocol reported, and — decisively — Morpheus8 was never given alone, so no part of the effect can be attributed to it specifically. The Baker classification is a coarse ordinal scale. And this is not an independent replication of source 9: n, baseline Baker score, improvement, satisfaction and all three complication rates are identical to the 247-patient cohort described in the 2019 supplement article, so the two papers should be counted as one series.Funding / interest: Declared, verbatim: 'Dr. Dayan is consultant at InMode; he receives book royalties from Thieme & Elsevier and is a co-investigator of Allergan, Galderma, and MTF. Dr. Rovatti is consultant at InMode. Dr. Aston is consultant at InMode. Dr. Chia is consultant at InMode. Dr. Rohrich receives book royalties from Thieme and instrument royalties from Micrins. He is a co-investigator of Allergan, Galderma, MTF, and InMode. Dr. Theodorou is consultant at InMode.' All six authors have a declared InMode relationship.
  11. Hamadani F, Vranis NM. The Role of Fractional Radiofrequency in Long-term Acne Remission and Reduction of Acne Scar Load. Aesthet Surg J. 2025;45(Suppl 1):S23-S31. doi:10.1093/asj/sjae150; published online 16 January 2025. (PubMed's summary field indexes the supplement as 'Suppl 2'; the publisher and PMC records both read 'Suppl 1'.)Tier 3Supports: Retrospective single-practice review naming the device explicitly: 'The Morpheus8 (InMode Ltd, Lake Forest, CA) is a fractional radiofrequency (RF) system that delivers thermal energy to variable depths of the skin through 24 parylene-coated gold-plated pins', with 'The distal part of the tip, which is uncoated' creating the coagulation zone — this is the only source in this package that describes the pin coating at all. Between February 2018 and October 2021, 356 patients received acne and early acne scar treatment in three non-randomised groups: high-dose isotretinoin plus topical therapy (n=128, 36%), a 6-session ablative laser series (n=89, 25%) and a 3-session fractional RF microneedling series (n=139, 44%). Among patients reaching 3-year follow-up, relapse rates were: isotretinoin 36/54 (67%), laser 12/16 (75%), fractional RF microneedling 7/29 (24%). Scope limits, and they are large: allocation was by clinical choice not randomisation; groups are not comparable at baseline; there is no blinded assessment; and only 29 of 139 RF-treated patients (21%) reached the 3-year timepoint that generates the headline number, against 54/128 (42%) in the isotretinoin arm and 16/89 (18%) in the laser arm. Follow-up that incomplete, and that unevenly distributed across arms, can move the result in either direction and is not adjusted for.Funding / interest: Declared: 'Drs Hamadani and Vranis are consultants for InMode Ltd (Lake Forest, CA).' Funding: 'This study was not directly funded or supported by industry; the machine and disposable costs required for the study were paid by the senior author.' Supplement sponsorship: 'This article appears as part of the supplement "The Use of Radiofrequency in the Face and Body," sponsored by InMode Ltd.'
  12. Safir A, Taleb E, Berzin D, Arieli M, Liassidou A, Shehadeh W, Hafner A, Artzi O. Fractional Microneedling Radiofrequency for Hidradenitis Suppurativa: A Real-World Retrospective Study Demonstrating Clinical Efficacy and Safety Across Diverse Anatomical Sites. J Cosmet Dermatol. 2026;25(3):e70748. doi:10.1111/jocd.70748. PMID 41732823.Tier 3Supports: Retrospective analysis at a tertiary dermatology centre (Tel Aviv Sourasky) of 25 hidradenitis suppurativa patients treated with 'Morpheus8-based FMR'; 17 who completed at least 2 sessions entered the efficacy analysis. Results: 16/17 (94.1%) showed clinical improvement; 9/17 (52.9%) achieved IHS4-55 (at least 55% reduction in the International Hidradenitis Suppurativa Severity Score System); mean IHS4 reduction 4.6 +/- 2.5. Response was highest at face, chest and gluteal regions and lowest at groin and thigh (face n=6, mean IHS4 reduction 6.3 with 50% reaching IHS4-55; groin 25% reaching IHS4-55, mean reduction 2.8). High-frequency ultrasound in three illustrative patients showed 'reduced dermal thickness, increased echogenicity, decreased sinus tract size, and diminished Doppler signal'. Safety: pain was the commonest reason for discontinuation, in 3 of 25 patients (12%), and one patient developed a post-treatment chest abscess requiring hospitalisation and intravenous antibiotics — the only serious adverse event recorded. Scope limits: retrospective, single centre, no control arm, no blinding, small n, and the efficacy denominator (17) excludes the 8 patients who did not complete two sessions — a per-protocol analysis that flatters the result. Hidradenitis suppurativa is a medical condition; in the UK this is disease treatment, not a cosmetic procedure.Funding / interest: Declared: 'Prof. Ofir Artzi serves occasionally as a key opinion leader for InMode Ltd. and holds a small, noninfluential personal shareholding in the company. All other authors declare no conflicts of interest.' Funding statement: 'The authors have nothing to report.'
  13. Garcés E, Parra LA, Martinez Amado A, Murúa E, Argueta J, Bugallo A, Parra AM. Low-energy Morpheus8 and Nanofat Grafting for Compartment-specific Facial Rejuvenation: Selective Fat Remodeling and Skin Quality Enhancement. Plast Reconstr Surg Glob Open. 2025;13(10):e7185.Tier 3Supports: Retrospective analysis of 20 patients (19 women, 1 man) aged 20-45 given nanofat injections immediately after low-energy Morpheus8 RF microneedling. Crucially, and omitted from the earlier reading of this source: all 20 were patients 'undergoing facial plastic surgery (eg, rhinoplasty, blepharoplasty, submental liposuction, and lipofilling for volume restoration)' who 'received adjunctive microneedle RF and nanofat treatment' in the same session — so three interventions are confounded, not two. Global Aesthetic Improvement Scale improved from a mean 3.35 (SD 0.61) pre-treatment to 1.76 (SD 0.87) post-treatment (P < 0.001) and 1.52 (SD 0.63) at 3 months (P < 0.001), with 85% rated 'very much improved'. Nine blinded evaluators reported reduced pore visibility, increased luminosity and diminished fine wrinkles in the malar and perioral regions — that is, in regions not operated on. No adverse events reported. Scope limits: n=20, retrospective, no control or split-face comparison, narrow age band (20-45, i.e. not the laxity population Morpheus8 is marketed to), and the interventions were given together so the Morpheus8 contribution cannot be isolated. GAIS was assessed at 1, 3 and 12 months, with standardised photographs at 6 and 12 months. The authors say so themselves: 'Future studies must include control arms to isolate the adjunctive role of combined RF-nanofat therapy', and 'Larger controlled studies are warranted to establish causality.' This is one of very few Morpheus8 papers with no declared InMode relationship.Funding / interest: Declared: 'The authors have no financial interest to declare in relation to the content of this article.'
  14. O'Daniel TG, Patton S. Neck Lift After Nonsurgical Treatments: Fibrosis, Fat Loss, and Surgical Complexity. Aesthet Surg J. 2026;46(4):372-383. doi:10.1093/asj/sjaf149; published online 25 July 2025, April 2026 issue.Tier 3Supports: Retrospective review of 180 neck lift procedures performed by a single surgeon in 2023. 123/180 (68%) 'had had previous neck treatments, including surgical neck lift and/or noninvasive therapies including chemolipolysis (Kybella), cryolipolysis (CoolSculpting), radiofrequency-assisted lipolysis (FaceTite, Morpheus8, SmartLipo, Ultherapy, Profound), and suture suspension (MyEllevate, PDO threads)'. Intraoperative findings in previously treated patients: 'fibrosis, loss of normal tissue planes, platysma and deep fascia rigidity, and unpredictable fat distribution'. Deep cervicoplasty with management of subplatysmal structures was required in 94% of cases; operative time increased in all cases; and although no major complications occurred, 'nearly all patients exhibited contour irregularities postoperatively from the destruction of the supraplatysmal fat and platysma'. Scope limits, and they matter: Morpheus8 is pooled with eight other named non-surgical modalities plus prior surgical neck lift, so nothing here is attributable to Morpheus8 specifically; the paper's own bracketing of Morpheus8 under 'radiofrequency-assisted lipolysis' is itself loose, since Morpheus8 is not a lipolysis device; this is a single-surgeon secondary-surgery series with obvious selection bias (only patients who went on to want surgery are counted); and no unexposed comparator is analysed. It is nonetheless the only peer-reviewed source describing what treated tissue looks like at operation.Funding / interest: Declared, verbatim: 'The authors declared no potential conflicts of interest with respect to the research, authorship, and publication of this article.' Funding: 'The authors received no financial support for the research, authorship, and publication of this article.' (An earlier reading of this source wrongly recorded that no disclosure statement existed; it does, and it is a clean one — this is an independent source.)
  15. US Food and Drug Administration. Potential Risks with Certain Uses of Radiofrequency (RF) Microneedling — FDA Safety Communication. Date issued 15 October 2025.Tier 1Supports: FDA statement, verbatim: 'With use of these devices for dermatologic or aesthetic procedures intended to improve the appearance of the skin (to treat wrinkles or to achieve skin effects, sometimes referred to as resurfacing, "tightening" or "rejuvenation"), the FDA is aware of reports of serious complications (adverse events) including burns, scarring, fat loss, disfigurement, and nerve damage, and the need for surgical repair or medical intervention to treat injuries.' It adds: 'While the FDA's evaluation is ongoing' and says it is working with manufacturers to evaluate the issue and identify mitigation strategies. Scope limits: this is a US safety communication about the RF microneedling device class; it does not name Morpheus8, quantify incidence, establish causality for an individual report, or carry direct UK legal force.